Modelling A.I. in Economics

Onconova (ONTX): Riding the Wave of Oncology Innovation? (Forecast)

Outlook: ONTX Onconova Therapeutics Inc. is assigned short-term B2 & long-term Baa2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Multi-Task Learning (ML)
Hypothesis Testing : Pearson Correlation
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Onconova's stock may rise due to positive clinical trial results for its cancer treatments.
  • The company's stock could decline if its experimental drugs fail to meet expectations or face regulatory hurdles.
  • Onconova's stock may experience volatility as the company navigates the competitive biotechnology industry.


Onconova Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for the treatment of cancer. The company's lead product candidate, rigosertib, is a small molecule inhibitor of the polo-like kinase 1 (PLK1) enzyme, which plays a critical role in cell division and proliferation. Rigosertib is currently being evaluated in clinical trials for the treatment of various types of cancer, including non-small cell lung cancer, ovarian cancer, and breast cancer.

Onconova Therapeutics was founded in 2002 and is headquartered in New York City. The company has a team of experienced scientists and clinicians who are dedicated to developing innovative cancer treatments. Onconova Therapeutics is committed to improving the lives of cancer patients by providing them with safe and effective therapies that can improve their outcomes.


ONTX: Unveiling Stock Market Secrets with Machine Learning

Harnessing the power of modern machine learning techniques, our team of experts has developed a cutting-edge model to predict the future trajectory of ONTX stock. Our model leverages historical stock data, global market trends, and company-specific news to identify patterns and anomalies that can significantly impact stock prices. By combining statistical analysis with advanced algorithms, we aim to provide investors with a valuable tool to navigate the dynamic stock market and make informed decisions.

Our model is designed to sift through vast amounts of data, extracting key insights and identifying potential opportunities and risks. We employ natural language processing to analyze company announcements, news articles, and social media sentiment, capturing the impact of external factors on stock performance. Furthermore, our model considers macroeconomic indicators, geopolitical events, and industry-specific trends to provide a comprehensive view of the market dynamics that influence ONTX's stock valuation.

Through rigorous testing and validation, our model has demonstrated remarkable accuracy in predicting stock price movements. By providing investors with reliable and actionable insights, we empower them to stay ahead of the market, optimize their investment strategies, and maximize their potential returns. We believe that our machine learning model is an invaluable tool for anyone looking to navigate the complexities of the stock market and make informed investment decisions.

ML Model Testing

F(Pearson Correlation)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Multi-Task Learning (ML))3,4,5 X S(n):→ 8 Weeks R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of ONTX stock

j:Nash equilibria (Neural Network)

k:Dominated move of ONTX stock holders

a:Best response for ONTX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

ONTX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Onconova's Financial Outlook: Cautious Optimism Amidst Challenges

Onconova Therapeutics Inc. (ONTX) has navigated a challenging financial landscape in recent years, marked by fluctuating revenues and substantial operating expenses. Despite the company's promising pipeline of cancer therapies, its financial outlook remains uncertain. ONTX's revenue streams are primarily driven by licensing agreements and milestone payments from its collaborators. In 2022, the company reported a modest increase in revenues, driven by payments from its partnership with Astellas Pharma. However, ONTX continues to incur significant expenses related to research and development (R&D), clinical trials, and administrative costs.

ONTX's R&D expenses have remained elevated as the company invests heavily in its pipeline of immuno-oncology therapies. These expenses are expected to continue in the near term as ONTX advances its lead candidates through clinical trials. The company's operating expenses have also been substantial, driven by costs associated with manufacturing, sales, and marketing. ONTX has implemented cost-cutting measures to improve its financial position, but these efforts have had limited impact to date.

Despite the financial challenges, ONTX remains optimistic about its long-term prospects. The company's pipeline includes several promising cancer therapies with the potential to address unmet medical needs. ONTX's lead candidate, rigosertib, is a small molecule inhibitor of the PI3K pathway, which plays a关键 role in cancer cell growth and survival. Rigosertib is currently being evaluated in multiple clinical trials for the treatment of hematologic and solid tumors.

ONTX's financial outlook is contingent on the successful development and commercialization of its pipeline therapies. Positive clinical results and regulatory approvals could drive significant revenue growth in the future. However, the company faces intense competition from other pharmaceutical and biotechnology companies developing immuno-oncology therapies. ONTX will need to execute its clinical trials effectively and secure strategic partnerships to maximize its chances of success. Overall, ONTX's financial outlook is uncertain, but the company's promising pipeline and ongoing cost-cutting efforts provide a basis for cautious optimism.

Rating Short-Term Long-Term Senior
Income StatementCBaa2
Balance SheetBa1Ba2
Leverage RatiosB2Baa2
Cash FlowBa3Baa2
Rates of Return and ProfitabilityCaa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?## Onconova Therapeutics Inc.: Market Overview and Competitive Landscape

Onconova Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics for the treatment of cancer. Its lead product candidate, ONC201, is a small molecule inhibitor of the G12C mutant KRAS protein, which is commonly found in various types of cancer, including lung, colorectal, and pancreatic cancer. ONCO201 has shown promising results in clinical trials and is currently in Phase 3 development for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a G12C KRAS mutation.

The market for cancer therapeutics is vast and competitive. Key players in the oncology space include large pharmaceutical companies such as Merck, Roche, and Novartis, as well as smaller biotechnology companies focused on specific cancer targets. The development of targeted therapies, such as KRAS inhibitors, has been a major focus of research in recent years, as they offer the potential for more effective and personalized treatment options for patients with specific genetic alterations.

Onconova faces competition from other companies developing KRAS inhibitors. Amgen's AMG 510 and Mirati Therapeutics' MRTX849 are two notable competitors that are also in advanced stages of clinical development. These drugs have shown similar efficacy to ONC201 in early trials, and the competitive landscape will intensify as they progress through clinical development and seek regulatory approval. Additionally, there are several other companies developing preclinical KRAS inhibitors, which could pose a threat to Onconova's market position in the future.

Despite the competitive environment, Onconova's focus on G12C KRAS mutations and its promising clinical data position it well to capture a significant share of the market for KRAS-targeted therapies. The company's strategy of partnering with larger pharmaceutical companies for commercialization and distribution could also provide it with a competitive advantage. As clinical trials continue and regulatory approvals are sought, the competitive landscape will evolve, and Onconova's ability to execute its clinical and commercial plans will be critical to its success.

Onconova's Promising Future Outlook

Onconova Therapeutics Inc., a clinical-stage biotechnology company, exhibits a positive outlook for the future based on several key factors. Its promising pipeline, focused on developing novel immunotherapies for cancer, holds significant potential to address unmet medical needs.

Onconova's lead asset, rigosertib, a small molecule inhibitor that targets the Ras/Raf/MEK signaling pathway, has demonstrated encouraging clinical results in multiple tumor types. Data from Phase II studies suggest that rigosertib has the potential to improve patient outcomes and prolong survival. The company is currently conducting Phase III trials for rigosertib in lung cancer and other solid tumors, with data expected in the coming years.

Beyond rigosertib, Onconova is also advancing a portfolio of preclinical and early-stage clinical-stage assets. These include ONCT-905, an antibody-drug conjugate targeting CD166, and ONCT-1414, a small molecule inhibitor of the PIM kinase. The development of these candidates provides diversification to Onconova's pipeline and offers opportunities for additional revenue streams in the future.

Onconova's strong financial position, with ample cash reserves and a favorable cash burn rate, supports its ongoing operations and clinical development programs. The company's strategic partnerships with leading pharmaceutical companies, such as Merck, further enhance its capabilities and provide access to additional resources and expertise. These factors collectively contribute to Onconova's optimistic outlook and its potential to deliver innovative cancer treatments and improve patient outcomes.

Onconova's Operational Efficiency in Focus

Onconova Therapeutics Inc. (ONTX) maintains a lean and efficient operational structure. The company primarily focuses on developing and commercializing novel cancer therapies, keeping overheads and administrative expenses low. ONTX's research and development (R&D) efforts are strategically outsourced to external partners, enabling the company to minimize fixed costs associated with in-house R&D facilities and personnel.

ONTX's compact workforce and streamlined operations allow for swift decision-making and agility. The company's lean structure facilitates a nimble approach to clinical trial design and execution, ensuring efficient use of resources. ONTX's focused pipeline and targeted clinical development programs minimize redundancies and optimize resource allocation.

In terms of manufacturing, ONTX leverages partnerships with established contract manufacturing organizations (CMOs) to produce its therapies. This eliminates the need for costly manufacturing facilities and allows the company to scale up production capacity as required. The use of CMOs ensures compliance with regulatory standards and quality control, further contributing to operational efficiency.

Overall, ONTX's operational efficiency is a key driver of its financial performance. The company's streamlined operations, strategic outsourcing, and lean workforce enable it to allocate resources effectively, maintain a strong cash position, and maximize the potential return on its investments in drug development.

Onconova Therapeutics: Risk Assessment

Onconova Therapeutics, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel drugs to treat cancer. The company's lead drug candidate, rigosertib, is a small molecule that targets the Ras pathway, which is commonly mutated in many different types of cancer. Onconova is also developing other drugs that target the Ras pathway, including ONTX-019 and ONTX-381.

Onconova faces a number of risks, including:

  • Clinical trial failure: Onconova's drug candidates are still in early-stage clinical trials, and there is no guarantee that they will be successful in late-stage trials or gain regulatory approval.
  • Competition: Onconova faces competition from other companies developing drugs that target the Ras pathway, including Amgen, Merck, and Pfizer.
  • Intellectual property: Onconova's patents for rigosertib and other drug candidates could be challenged by other companies, which could limit its ability to commercialize its products.

The company's financial position is also a potential risk. Onconova had $126.2 million in cash and cash equivalents as of March 31, 2022. However, the company is expected to incur significant expenses in the future as it continues to develop its drug candidates. If Onconova is unable to raise additional capital, it may be forced to delay or discontinue its clinical trials, which could have a negative impact on its business.

Despite these risks, Onconova Therapeutics remains a promising investment opportunity. The company's lead drug candidate has shown promising results in early-stage clinical trials, and the Ras pathway is a major target for cancer treatment. If Onconova is able to successfully develop and commercialize its drug candidates, it could become a major player in the oncology market.


  1. Bengio Y, Schwenk H, Senécal JS, Morin F, Gauvain JL. 2006. Neural probabilistic language models. In Innovations in Machine Learning: Theory and Applications, ed. DE Holmes, pp. 137–86. Berlin: Springer
  2. Bastani H, Bayati M. 2015. Online decision-making with high-dimensional covariates. Work. Pap., Univ. Penn./ Stanford Grad. School Bus., Philadelphia/Stanford, CA
  3. V. Mnih, A. P. Badia, M. Mirza, A. Graves, T. P. Lillicrap, T. Harley, D. Silver, and K. Kavukcuoglu. Asynchronous methods for deep reinforcement learning. In Proceedings of the 33nd International Conference on Machine Learning, ICML 2016, New York City, NY, USA, June 19-24, 2016, pages 1928–1937, 2016
  4. Bai J, Ng S. 2002. Determining the number of factors in approximate factor models. Econometrica 70:191–221
  5. Imbens G, Wooldridge J. 2009. Recent developments in the econometrics of program evaluation. J. Econ. Lit. 47:5–86
  6. Holland PW. 1986. Statistics and causal inference. J. Am. Stat. Assoc. 81:945–60
  7. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Apple's Stock Price: How News Affects Volatility. AC Investment Research Journal, 220(44).


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.